In addition, patients with hereditary breast and ovarian cancers and P/LP variants in BRCA2 have been shown to have significantly lower AMH levels than controls (68), and 2 of our patients with P/LP variants in BRCA2 had low AMH (patients 1093 and 1985; Supplemental Table 2). This evidence concerns the gene AMH and ovarian carcinoma.